AlphAIAlphAI — Financial news for AI agents
finanznachrichten.deOCT 192 min read$EVAX

Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion A/S (NASDAQ: EVAX) reported sustained clinical responses for all patients at three-year follow-up in a phase 2 trial for its personalized cancer vaccine EVX-01 in advanced melanoma. The data, to be presented at ESMO 2026, showed a 75% objective response rate with 25% of patients achieving complete response. EVX-01 will be discussed in a webinar and poster session.

Original reporting
finanznachrichten.de
Published Oct 19, 2026, 9:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 6:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$EVAX
Bullish
high confidence
Mentioned
$EVAX
Relevance
8/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$EVAXBullishMed
01

Why it matters

The three‑year data reinforce the durability of EVX‑01, supporting the company's valuation and partnership prospects.

02

Market read

Positive trial data for a niche biotech can trigger a short‑term rally and influence sentiment toward AI‑driven immunotherapy stocks.

03

What to watch

Potential regulatory hurdles and the need for partnership funding could temper upside despite positive data.

Relevance 8/10Novelty 8/10Timing: today

Background

Evaxion is a clinical‑stage TechBio company using its AI‑Immunology platform to develop personalized cancer vaccines.

Company-level read

Ticker impact

$EVAXBullishHigh confidence
Context

Evaxion disclosed three-year follow‑up data showing sustained clinical responses and no tumor progression in its phase‑2 melanoma vaccine trial.

Expected impact

likely upward pressure as investors price in durable efficacy data

Evidence & confidence

First disclosure of durable three‑year data for a biotech candidate is material and can move the stock immediately.

Market effects

Sector

Strengthens the personalized cancer‑vaccine segment and may benefit peers developing AI‑driven immunotherapies.

Regional

European biotech investors may see increased interest in Copenhagen‑based firms.

Global

Adds credibility to AI‑based drug discovery, a trend of global interest.

Counterpoint

What could challenge this read

The small patient cohort and early‑stage trial may limit the long‑term impact; investors should watch for larger Phase‑3 data before committing.

Key entities

  • company
    Evaxion A/S

    Clinical‑stage biotech developing personalized cancer vaccines.

  • company
    Merck & Co., Inc.

    Provided anti‑PD‑1 therapy (Keytruda) used in combination with EVX‑01.

Read at source← All news

StoryEvaxion reports three-year durability and immune data for melanoma vaccine

Also covered by

1 outlet

Related articles

OCT 23
$EVAXMedAI 8/10

Evaxion reports three-year data for cancer vaccine EVX-01

Evaxion A/S (EVAX) reported three-year phase 2 trial data for its cancer vaccine EVX-01, showing sustained immune response and no tumor progression in advanced melanoma patients. The data will be presented at the ESMO Congress 2026. EVX-01 is personalized and designed using Evaxion's AI-Immunology platform. The company has a cash runway into mid-2027.

investing.com2 min
OCT 23
$EVAXMedAI 9/10

Six melanoma responders received Evaxion's vaccine alone in year three. None had tumor progression.

Evaxion A/S (NASDAQ: EVAX) reported three-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. All six patients in the trial's extension showed no tumor progression, maintaining responses seen at two years. The data will be presented at ESMO 2026. EVX-01 induced an immune response in all patients, with 89% of vaccine neoantigens generating potent T-cell responses.

stocktitan.net2 min
OCT 19
$EVAXHighAI 8/10

Evaxion stock surges on 3-year melanoma vaccine trial data

Evaxion AS ADR (EVAX) shares rose 21.6% after reporting 3-year data from its EVX-01 phase 2 trial in advanced melanoma patients. All patients maintained clinical responses with no tumor progression. The data will be presented at ESMO Congress 2026. EVX-01 is a personalized cancer vaccine developed using AI-Immunology platform.

investing.com2 min
OCT 19
$EVAXMedAI 8/10

Evaxion Reports Durable Three-Year Responses With EVX-01 In Advanced Melanoma

Evaxion A/S reported that patients in a Phase 2 study of its personalized cancer vaccine EVX-01 for advanced melanoma maintained responses for three years, with no tumor progression. The company will present the data at ESMO 2026, showing a 75% response rate and 92% clinical benefit at two years. EVX-01 is currently in development for advanced solid tumors. EVAX stock closed at $2.83 on October 16, 2026, and is up 2.83% in pre-market trading.

rttnews.com2 min